Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis-Reference-Cited by-同舟云学术

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis

Published:2018-01 Issue: Volume:11 Page:175628641879508
ISSN:1756-2864
Container-title:Therapeutic Advances in Neurological Disorders
language:en
Short-container-title:Ther Adv Neurol Disord

Author:

Arnold Douglas L.¹,Shang Shulian²,Dong Qunming²,Meergans Matthias³,Naylor Maria L.⁴

Affiliation:

1. Montreal Neurological Institute, McGill University, and NeuroRx Research, Montreal, QC, Canada

2. Biogen, Cambridge, MA, USA

3. Biogen, Zug, Switzerland

4. Biogen, 225 Binney St., Cambridge, MA 02142, USA

Funder

Biogen

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology,Pharmacology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1756286418795085

Reference21 articles.

1. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

2. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

3. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists;American Journal of Health-System Pharmacy;2023-10-01

2. Association of No Evidence of Disease Activity With No Long-term Disability Progression in Multiple Sclerosis;Neurology;2022-04-26

3. Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors?;Drug Discovery Today;2021-02

4. Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate;Therapeutic Advances in Neurological Disorders;2021-01

5. “No evidence of disease activity”: Is it an aspirational therapeutic goal in multiple sclerosis?;Multiple Sclerosis and Related Disorders;2020-05